Neteka (Baclofen)

Baclofen acts as an agonist at GABA_B receptors in the spinal cord and brainstem. By activating these receptors, it reduces excitatory neurotransmitter release, dampens neuronal firing, and ultimately lowers the hyperactive reflex pathways that cause spastic muscle tone.

The dosage of intrathecal baclofen is individualized. A qualified prescriber determines the starting dose and titration schedule based on the patient’s clinical condition, response, and tolerance. Specific dosing regimens are not provided here and must follow the prescribing information.

Safety data for intrathecal baclofen in pregnancy and lactation are limited. Use is recommended only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with an obstetric specialist is essential before initiating therapy.

To request Neteka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Neteka delivers baclofen directly into the intrathecal space, achieving higher spinal concentrations with lower systemic exposure compared with oral baclofen. This route often provides superior spasticity control and fewer systemic side effects than oral agents or other muscle relaxants such as tizanidine, especially in patients who do not respond adequately to oral therapy.

Neteka should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow aseptic techniques during preparation and administration to maintain sterility.

Neteka is administered as a sterile solution via an implanted intrathecal pump or catheter system. The medication is delivered directly into the cerebrospinal fluid, allowing precise control of dosing and continuous infusion to manage spasticity.

The most serious risks include respiratory depression, severe hypotension, and baclofen withdrawal syndrome, which can occur if the infusion is abruptly stopped. Patients should be monitored closely for signs of breathing difficulty, sudden drops in blood pressure, or a rapid return of spasticity and related symptoms.

Neteka is contraindicated in individuals with known hypersensitivity to baclofen or any component of the formulation. Caution is also advised for patients with uncontrolled epilepsy, severe cardiac disease, or those who cannot undergo intrathecal catheter implantation. The prescribing clinician must evaluate each patient’s suitability before initiating therapy.